Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Edwards Lifesciences Corporation
Edwards Lifesciences Corporation News
Edwards Lifesciences Corporation Quantitative Score
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Edwards Lifesciences Corporation Earnings & Revenue
Edwards Lifesciences Corporation Financials
Table Compare
Compare EW metrics with: | |||
|---|---|---|---|
Earnings & Growth | EW | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | EW | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | EW | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | EW | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Edwards Lifesciences Corporation Income
Edwards Lifesciences Corporation Balance Sheet
Edwards Lifesciences Corporation Cash Flow
Edwards Lifesciences Corporation Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Edwards Lifesciences Corporation Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Edwards Lifesciences Corporation Executives
| Name | Role |
|---|---|
| Mr. Bernard J. Zovighian | Chief Executive Officer & Director |
| Mr. Larry L. Wood | Corporate Vice President and Group President of TAVR & Surgical Structural Heart |
| Mr. Scott B. Ullem | Corporate Vice President & Chief Financial Officer |
| Mr. Donald E. Bobo Jr. | Corporate Vice President of Strategy & Corporate Development |
| Mr. Mark Wilterding | Vice President of Investor Relations |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Bernard J. Zovighian | Chief Executive Officer & Director | Male | 1968 | 2.27M |
| Mr. Larry L. Wood | Corporate Vice President and Group President of TAVR & Surgical Structural Heart | Male | 1966 | 1.49M |
| Mr. Scott B. Ullem | Corporate Vice President & Chief Financial Officer | Male | 1967 | 1.35M |
| Mr. Donald E. Bobo Jr. | Corporate Vice President of Strategy & Corporate Development | Male | 1962 | 1.27M |
| Mr. Mark Wilterding | Vice President of Investor Relations | Male | -- |
Edwards Lifesciences Corporation Insider Trades
| Date | 16 Dec |
| Name | Lippis Daniel J. |
| Role | CVP, JAPAC |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 2500 |
| Date | 16 Dec |
| Name | Lippis Daniel J. |
| Role | CVP, JAPAC |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 2500 |
| Date | 16 Dec |
| Name | Lippis Daniel J. |
| Role | CVP, JAPAC |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 2500 |
| Date | 9 Dec |
| Name | Ullem Scott B. |
| Role | CVP, Chief Financial Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 11250 |
| Date | 9 Dec |
| Name | Ullem Scott B. |
| Role | CVP, Chief Financial Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 11250 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 16 Dec | Lippis Daniel J. | CVP, JAPAC | Acquired | M-Exempt | 2500 |
| 16 Dec | Lippis Daniel J. | CVP, JAPAC | Disposed | S-Sale | 2500 |
| 16 Dec | Lippis Daniel J. | CVP, JAPAC | Disposed | M-Exempt | 2500 |
| 9 Dec | Ullem Scott B. | CVP, Chief Financial Officer | Acquired | M-Exempt | 11250 |
| 9 Dec | Ullem Scott B. | CVP, Chief Financial Officer | Disposed | S-Sale | 11250 |